Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 239 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Small Cell Lung Cancer Clear all
Completed Phase 1Phase 2 Interventional

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

NCT00397293
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AT-101, topotecan
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 24, 2026, 4:33 AM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00006347
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Oct 24, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Ifinatamab Deruxtecan (I-DXd)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

NCT00921310
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pemetrexed, Temsirolimus
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 24, 2026, 4:33 AM EDT
Recruiting Phase 1 Interventional

AOH1996 for the Treatment of Refractory Solid Tumors

NCT05227326
View directory record Official record
Conditions
Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer
Interventions
PCNA Inhibitor AOH1996
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

NCT00019513
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

NCT02403271
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions
Ibrutinib, Durvalumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00064350
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
141
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 24, 2026, 4:33 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Terminated Phase 1 Interventional

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 24, 2026, 4:33 AM EDT
Terminated Phase 1 Interventional Results available

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

NCT05130255
View directory record Official record
Conditions
SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
Interventions
GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Terminated Phase 1 Interventional Results available

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

NCT04081688
View directory record Official record
Conditions
Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

NCT00521144
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 24, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

NCT02706626
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
brigatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218
View directory record Official record
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 24, 2026, 4:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
BMS-986012 (anti-fucosyl-GM1), Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

NCT00282022
View directory record Official record
Conditions
Lung Cancer
Interventions
laromustine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • West Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 24, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

NCT01994382
View directory record Official record
Conditions
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions
Cerdulatinib, Rituximab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
23
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 24, 2026, 4:33 AM EDT
Not listed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00006458
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Oct 24, 2026, 4:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016
View directory record Official record
Conditions
Relapsed/Refractory Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 4:33 AM EDT